Dianomi Therapeutics gets $3M boost

Dianomi Therapeutics, a Madison startup studying how prescribed medications can better reduce pain at the source, received a $3 million investment from San Diego-based Ligand Pharmaceuticals in a vote of confidence for the future.

The investment will allow Ligand to receive 2 to 3 percent of sales royalties for the first five of Dianomi’s products, which may not even hit the market for another five years or so, according to a Ligand release.

Dianomi’s research, which currently targets osteoarthritis, or degenerative joint pain, is based on research conducted by UW–Madison biomedical engineer and professor Bill Murphy and patented by the Wisconsin Alumni Research Foundation (WARF).